FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Fournier Pharma

Cipher receives Health Canada approval of CIP-Fenofibrate

22-Feb-2006 - Cipher Pharmaceuticals Inc. announced that it has received final approval from Health Canada for CIP-Fenofibrate, the Company's novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. Health Canada has issued a Notice of Compliance for ...

food

Solvay finalizes agreement to buy Fournier Pharma

14-Jul-2005 - Solvay announced today that it has signed a final purchase agreement with the shareholders of Fournier Pharma for the acquisition of 100% of the company. Substantial social and regulatory procedures have been successfully completed worldwide. The transaction, which now only awaits approval from ...

Abbott blood lipids Solvay

Fournier Pharma and Xytis Pharmaceutcials sign licensing agreement for Anatibant

14-Jun-2005 - Fournier Pharma and Xytis Pharmaceuticals Ltd. announced that they have signed an agreement for the development and commercialisation of Anatibant (LF16-0687MS), a potential new medication for the treatment of traumatic brain injury, originating from Fournier Pharma's Research. Fournier Pharma ...

clinical trials inhibitors

Cipher reaches agreement to dismiss patent litigation in United States for CIP-Fenofibrate

01-Jun-2005 - Cipher Pharmaceuticals Inc. announced that it has reached an agreement with Abbott Laboratories, Fournier Industrie et Santé and Laboratoires Fournier S.A. to dismiss all claims in the U.S. patent litigation related to CIP-Fenofibrate, Cipher's formulation of the active ingredient fenofibrate, ...

Abbott cholesterol food +1